- Abrocitinib monotherapy is associated with good clinical efficacy and is well-tolerated in adolescents and adults with moderate-to-severe atopic dermatitis.
- Results are from the JADE MONO-2 phase 3 randomized controlled trial (RCT).
Why this matters
- These results support findings from JADE MONO-1, an earlier phase 3 trial of abrocitinib.
- Abrocitinib was associated with superior efficacy compared with placebo:
- Investigator’s Global Assessment score 0/1: 38.1% for 200 mg, 28.4% for 100 mg, 9.1% for placebo (P<.001>
- 75% improvement in Eczema Area and Severity Index score: 61.0% for 200 mg, 44.5% for 100 mg, 10.4% for placebo (P<.001>
- ≥4-point improvement in Peak Pruritus Numerical Rating Scale: 55.3% for 200 mg, 45.2% for 100 mg, 11.5% for placebo (P≤.001).
- Rates of serious adverse events were 1.3%, 3.2%, and 1.3%, respectively.
- Included 391 patients with moderate-to-severe atopic dermatitis, 155 who received 200 mg abrocitinib, 158 who received 100 mg abrocitinib, and 78 who received placebo.
- Efficacy and safety outcomes were assessed.
- Funding: Pfizer Inc.
- Short treatment duration and follow-up.